Preclinical: (i) Improves cisplatin-induced anorexia (decreases plasma-acylated ghrelin level and enhances food intake) by acting as antagonists at the 5-HT2B/2C receptors. Clinical: (i) Improves CINV by mediating 5-HT2B/2C receptors and ghrelin receptor signaling; (ii) gastroprotective actions: enhances gastric motility through the 5-HT3 receptor-antagonistic effect; (iii) appetite-stimulating effect via mediating ghrelin receptor signaling (blocked by (D-Lys3)-GHRP-6). This evidence concerns the gene GHRL and Anorexia.